がん臨床判断ツールの世界市場レポート 2025年

がん臨床判断ツール市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で7億9,000万米ドルに成長します。予測期間の成長は、世界の高齢化、患者エンゲージメントと意思決定の共有、患者中心のケア、臨床研究、エビデンスに基づく医療に起因すると考えられます。予測期間の主な動向には、医療画像の進歩、AI主導の臨床意思決定支援、遠隔医療と遠隔診察、予測分析、相互運用性とデータ標準、倫理的・規制的配慮などが含まれます。

世界のがん患者数の増加は、がん臨床判断ツール市場の成長を促進する構えです。米国がん協会が2022年1月に発表したように、米国だけでも190万人が新たにがんと診断され、約60万9,360人ががん関連で死亡すると推定され、毎日約1,670人が死亡していることになります。肺がん、前立腺がん、腸がん、女性の乳がんは、合計で世界の新規がん患者の43％を占める。このような世界のがん罹患の急増により、がん臨床判断ツールに対する需要が高まり、治療方針の決定が迅速化され、その結果、これらのツールの市場が強化されると予測されます。

ヘルスケアITの普及は、がん臨床判断ツール市場を牽引する原動力になると予測されています。ヘルスケアITの導入とは、ヘルスケア領域における情報技術ソリューションの同化と利用を意味します。医療機関は、電子カルテ（EHR）や臨床意思決定支援システム（CDSS）を含む情報技術に戦略的に投資し、患者ケアの最適化を目指しています。これらのシステムは、リアルタイムの患者データ、治療ガイドライン、潜在的な問題に対する警告メカニズムを統合し、最終的にがん治療の転帰を向上させる。例えば、ヘルスケア情報管理システム学会（HIMSS）が2022年1月に発表した報告書によると、医療提供者の80％が今後5年間でテクノロジーへの投資を増強する予定であることが明らかになりました。このようなヘルスケアIT導入の動向は、がん臨床判断ツール市場の成長軌道を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がん臨床判断ツールPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがん臨床判断ツール市場：成長率分析
• 世界のがん臨床判断ツール市場の実績：規模と成長, 2019-2024
• 世界のがん臨床判断ツール市場の予測：規模と成長, 2024-2029, 2034F
• 世界がん臨床判断ツール総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがん臨床判断ツール市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リスク評価ツール（RAT）
• Qがん
• 世界のがん臨床判断ツール市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 世界のがん臨床判断ツール市場リスク評価ツール（RAT）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 家族歴評価
• 遺伝子検査とカウンセリング
• ライフスタイルと環境リスク要因の評価
• 世界のがん臨床判断ツール市場Qcancerのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 症状チェッカー
• リスク計算ツール
• ガイドラインに基づく推奨事項

第7章 地域別・国別分析

• 世界のがん臨床判断ツール市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがん臨床判断ツール市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん臨床判断ツール市場：競合情勢
• がん臨床判断ツール市場：企業プロファイル
  • McKesson Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Medical Information Technology Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Philips Healthcare Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • Elsevier B.V. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Macmillan Publishers Limited
• National Decision Support Company
• IBM Watson Health
• Cerner Corporation
• GE Healthcare
• Allscripts Healthcare Solutions Inc.
• Epic Systems Corporation
• Koninklijke Philips N.V.
• RaySearch Laboratories AB
• Elekta AB
• Varian Medical Systems Inc.
• Accuray Incorporated
• F. Hoffmann-La Roche Ltd.
• Flatiron Health Inc.
• Tempus Labs Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がん臨床判断ツール市場2029：新たな機会を提供する国
• がん臨床判断ツール市場2029：新たな機会を提供するセグメント
• がん臨床判断ツール市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cancer clinical decision tools are instrumental aids designed to support medical practitioners in identifying potential signs and symptoms of cancer, enabling more effective patient treatment. These tools play a crucial role in clinical decision-making by assisting General Practitioners (GPs) in determining whether further diagnostic testing or referrals are necessary for patients suspected of having cancer.

Among the primary types of cancer clinical decision tools are risk assessment tools (RAT) and Qcancer. Risk assessment tools evaluate a combination of risk factors, encompassing genetic, environmental, and behavioral elements, to translate these factors into estimations of an individual's likelihood of developing specific types of cancer. These tools serve to streamline risk models and facilitate assessments of an individual's cancer risk profile. These cancer clinical decision tools find application across various healthcare settings, including hospitals and clinics, supporting healthcare professionals in making informed decisions regarding patient care and potential referrals for further diagnostic assessments.

The cancer clinical decision tools market research report is one of a series of new reports from The Business Research Company that provides cancer clinical decision tools market statistics, including cancer clinical decision tools industry global market size, regional shares, competitors with a cancer clinical decision tools market share, detailed cancer clinical decision tools market segments, market trends and opportunities, and any further data you may need to thrive in the cancer clinical decision tools industry. This cancer clinical decision tools market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer clinical decision tools market size has grown strongly in recent years. It will grow from $0.5 billion in 2024 to $0.55 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to the growing prevalence of cancer, increasing complexity of cancer treatment, rising demand for personalized medicine, growing adoption of value-based healthcare, increasing availability of cancer data, and government support for cancer research and development.

The cancer clinical decision tools market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to global aging population, patient engagement and shared decision-making, patient-centric care, clinical research and evidence-based medicine. Major trends in the forecast period include advancements in medical imaging, AI-driven clinical decision support, telemedicine and remote consultations, predictive analytics, interoperability and data standards, and ethical and regulatory considerations.

The ascending global cancer cases are poised to fuel growth in the cancer clinical decision tools market. As highlighted by the American Cancer Society in January 2022, the US alone is estimated to witness 1.9 million new cancer diagnoses and approximately 609,360 cancer-related deaths, translating to roughly 1,670 fatalities daily. Lung, prostate, bowel, and female breast cancers collectively account for 43% of all new cancer cases worldwide. This surge in cancer incidents globally is projected to intensify the demand for cancer clinical decision tools, expediting treatment decisions and thereby bolstering the market for these tools.

The proliferation of healthcare IT adoption is anticipated to be a driving force behind the cancer clinical decision tools market. Healthcare IT adoption denotes the assimilation and usage of information technology solutions within the healthcare domain. Health institutions strategically invest in information technology, encompassing electronic health records (EHRs) and clinical decision support systems (CDSS), aiming to optimize patient care. These systems integrate real-time patient data, treatment guidelines, and alert mechanisms for potential issues, ultimately enhancing cancer treatment outcomes. For example, a report published by the Healthcare Information and Management Systems Society (HIMSS) in January 2022 indicated that a significant 80% of healthcare providers planned to augment their technology investments over the next five years. This trend in healthcare IT adoption is expected to propel the cancer clinical decision tools market's growth trajectory.

Key industry players in the cancer clinical decision tools market are exploring innovative offerings like the BenchMark Ultra Plus tissue staining system to gain a competitive edge. This advanced system streamlines tissue staining, enabling quicker and more accurate pathology outcomes. Launched by F. Hoffmann-La Roche AG in June 2022, the BenchMark Ultra Plus system showcases enhanced workflow efficiency, testing processes, and sustainability attributes. This innovation empowers pathologists to deliver high-quality, time-sensitive results to medical professionals and patients alike. The BenchMark Ultra Plus system marks a significant advancement in the BenchMark series, automating erstwhile manual slide-by-slide processes and revolutionizing cancer diagnostics.

In October 2022, Beckman Coulter Inc., a medical diagnostics company based in the United States, acquired StoCastic, LLC for an undisclosed amount. This acquisition is intended to enhance Beckman Coulter's capabilities in cancer diagnostics by incorporating advanced data analytics and clinical decision support tools developed by StoCastic, LLC. StoCastic, LLC is a U.S.-based biotechnology firm that focuses on creating advanced data analytics and clinical decision tools specifically for cancer diagnostics and treatment.

Major companies operating in the cancer clinical decision tools market include McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., Macmillan Publishers Limited, National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Oncora Medical Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc., Enlitic Inc., Ibex Medical Analytics Ltd., Zebra Medical Vision Ltd., Aidoc Medical Ltd.

North America was the largest region in the cancer clinical decision tools market in 2024. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer clinical decision tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The market for cancer clinical decision tools consists of sales of risk assessment tools, Q-Cancer tools, and MacMillan's cancer decision tool. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Clinical Decision Tools Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer clinical decision tools market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer clinical decision tools ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer clinical decision tools market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Risk Assessment Tool(RAT); Qcancer
• 2) By End-User: Hospital; Clinics
• Subsegments:
• 1) By Risk Assessment Tool (RAT): Family History Assessment; Genetic Testing and Counseling; Lifestyle and Environmental Risk Factors Evaluation
• 2) By Qcancer: Symptom Checker; Risk Calculator; Guideline-Based Recommendations
• Companies Mentioned: McKesson Corporation; Medical Information Technology Inc.; Philips Healthcare; Siemens Healthineers AG; Elsevier B.V.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Clinical Decision Tools Market Characteristics

3. Cancer Clinical Decision Tools Market Trends And Strategies

4. Cancer Clinical Decision Tools Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cancer Clinical Decision Tools Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Clinical Decision Tools PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Clinical Decision Tools Market Growth Rate Analysis
• 5.4. Global Cancer Clinical Decision Tools Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Clinical Decision Tools Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Clinical Decision Tools Total Addressable Market (TAM)

6. Cancer Clinical Decision Tools Market Segmentation

• 6.1. Global Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Risk Assessment Tool (RAT)
• Qcancer
• 6.2. Global Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinics
• 6.3. Global Cancer Clinical Decision Tools Market, Sub-Segmentation Of Risk Assessment Tool (RAT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Family History Assessment
• Genetic Testing and Counseling
• Lifestyle and Environmental Risk Factors Evaluation
• 6.4. Global Cancer Clinical Decision Tools Market, Sub-Segmentation Of Qcancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptom Checker
• Risk Calculator
• Guideline-Based Recommendations

7. Cancer Clinical Decision Tools Market Regional And Country Analysis

• 7.1. Global Cancer Clinical Decision Tools Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Clinical Decision Tools Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Clinical Decision Tools Market

• 8.1. Asia-Pacific Cancer Clinical Decision Tools Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Clinical Decision Tools Market

• 9.1. China Cancer Clinical Decision Tools Market Overview
• 9.2. China Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Clinical Decision Tools Market

• 10.1. India Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Clinical Decision Tools Market

• 11.1. Japan Cancer Clinical Decision Tools Market Overview
• 11.2. Japan Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Clinical Decision Tools Market

• 12.1. Australia Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Clinical Decision Tools Market

• 13.1. Indonesia Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Clinical Decision Tools Market

• 14.1. South Korea Cancer Clinical Decision Tools Market Overview
• 14.2. South Korea Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Clinical Decision Tools Market

• 15.1. Western Europe Cancer Clinical Decision Tools Market Overview
• 15.2. Western Europe Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Clinical Decision Tools Market

• 16.1. UK Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Clinical Decision Tools Market

• 17.1. Germany Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Clinical Decision Tools Market

• 18.1. France Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Clinical Decision Tools Market

• 19.1. Italy Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Clinical Decision Tools Market

• 20.1. Spain Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Clinical Decision Tools Market

• 21.1. Eastern Europe Cancer Clinical Decision Tools Market Overview
• 21.2. Eastern Europe Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Clinical Decision Tools Market

• 22.1. Russia Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Clinical Decision Tools Market

• 23.1. North America Cancer Clinical Decision Tools Market Overview
• 23.2. North America Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Clinical Decision Tools Market

• 24.1. USA Cancer Clinical Decision Tools Market Overview
• 24.2. USA Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Clinical Decision Tools Market

• 25.1. Canada Cancer Clinical Decision Tools Market Overview
• 25.2. Canada Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Clinical Decision Tools Market

• 26.1. South America Cancer Clinical Decision Tools Market Overview
• 26.2. South America Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Clinical Decision Tools Market

• 27.1. Brazil Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Clinical Decision Tools Market

• 28.1. Middle East Cancer Clinical Decision Tools Market Overview
• 28.2. Middle East Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Clinical Decision Tools Market

• 29.1. Africa Cancer Clinical Decision Tools Market Overview
• 29.2. Africa Cancer Clinical Decision Tools Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Clinical Decision Tools Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Clinical Decision Tools Market Competitive Landscape And Company Profiles

• 30.1. Cancer Clinical Decision Tools Market Competitive Landscape
• 30.2. Cancer Clinical Decision Tools Market Company Profiles
  • 30.2.1. McKesson Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Medical Information Technology Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Philips Healthcare Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Elsevier B.V. Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Clinical Decision Tools Market Other Major And Innovative Companies

• 31.1. Macmillan Publishers Limited
• 31.2. National Decision Support Company
• 31.3. IBM Watson Health
• 31.4. Cerner Corporation
• 31.5. GE Healthcare
• 31.6. Allscripts Healthcare Solutions Inc.
• 31.7. Epic Systems Corporation
• 31.8. Koninklijke Philips N.V.
• 31.9. RaySearch Laboratories AB
• 31.10. Elekta AB
• 31.11. Varian Medical Systems Inc.
• 31.12. Accuray Incorporated
• 31.13. F. Hoffmann-La Roche Ltd.
• 31.14. Flatiron Health Inc.
• 31.15. Tempus Labs Inc.

32. Global Cancer Clinical Decision Tools Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Clinical Decision Tools Market

34. Recent Developments In The Cancer Clinical Decision Tools Market

35. Cancer Clinical Decision Tools Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Clinical Decision Tools Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Clinical Decision Tools Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Clinical Decision Tools Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer